p53 prophylactic therapy for cancer prevention.

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Germline mutations in the TP53 tumor suppressor gene cause Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition.
• Currently, no preventative or delaying strategies exist for cancer development in LFS patients.

Purpose of the Study:

• To test the hypothesis that modulating wild-type p53 levels can serve as a prophylactic approach to mitigate cancer risk.
• To investigate the effects of introducing an additional copy of the Trp53 gene on tumor development and lifespan in cancer-prone mouse models.

Main Methods:

• Introduction of a third copy of the Trp53 gene (constitutively or inducibly) in adult mice.
• Evaluation of tumor development delay and lifespan extension in Eu-myc lymphoma and Li-Fraumeni syndrome (LFS) mouse models.
• Assessment of Trp53 loss of heterozygosity and p53 transcriptional response.

Main Results:

• Tumor development was delayed, and lifespan was extended in both mouse models without observable side effects.
• The LFS model showed reduced Trp53 loss of heterozygosity.
• An enhanced p53 transcriptional response was observed in the LFS model.

Conclusions:

• Genetic evidence supports modulating wild-type p53 levels as a viable prophylactic strategy against cancer.
• This approach could lead to the identification of compounds benefiting LFS carriers and other populations with reduced p53 activity.
• Further research could explore therapeutic compounds targeting p53 modulation for cancer prevention.